DNA vaccines for SARS-CoV-2: toward third-generation vaccination era
Vivek P. Chavda, Radhika Pandya, Vasso Apostolopoulos
Abstract
Through DNA vaccines, host cells are momentarily transformed into factories that produce proteins of the SARS-CoV-2. The host immune system detects these proteins to develop antibodies that neutralize and prevent the infection. This vaccine platform has additional benefits compared to traditional vaccination strategies like strong cellular immune response, higher safety margin, a simple production process as per cGMP norms, lack of any infectious agent, and a robust platform for large-scale production.
Topics & Concepts
PandemicVirologyDNA vaccinationCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationCoronavirus2019-20 coronavirus outbreakOutbreakImmune systemMedicineBiologyImmunologyImmunizationInfectious disease (medical specialty)DiseasePathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy